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INTRODUCTORY PARAGRAPH 
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to 
chemotherapy-resistant secondary acute myeloid leukemia (sAML).  We used whole genome 
sequencing to perform an unbiased comprehensive screen to discover all the somatic mutations 
in a sAML sample and genotyped these mutations in the matched MDS sample.  Here we show 
that a missense mutation affecting the serine at codon 34 (S34) in U2AF1 was recurrently 
mutated in 13/150 (8.7%) de novo MDS patients, with suggestive evidence of an associated 
increased risk of progression to sAML.  U2AF1 is a U2 auxiliary factor protein that recognizes 
the AG splice acceptor dinucleotide at the 3’ end of introns and mutations are located in highly 
conserved zinc fingers in U2AF11,2.  Mutant U2AF1 promotes enhanced splicing and exon 
skipping in reporter assays in vitro.  This novel, recurrent mutation in U2AF1 implicates altered 
pre-mRNA splicing as a potential mechanism for MDS pathogenesis. 
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MAIN TEXT 
 Myelodysplastic syndromes (MDS) are a heterogenous group of hematopoietic stem cell 
disorders characterized by dysplastic blood cell formation and peripheral blood cytopenias.  Up 
to 30% of patients with MDS will progress to a highly chemotherapy-resistant secondary acute 
myeloid leukemia (sAML).  Whole genome sequencing (WGS) offers an unbiased approach to 
discover all the genetic mutations present in cancer genomes and has been used to identify novel 
mutations in de novo and therapy-related AML genomes3-7.  Here we report the results of WGS 
of an MDS-derived sAML sample and the matched normal (skin) sample.  We performed WGS 
using 100 base pair paired-end reads and obtained 39.1x and 38.2x haploid and 99.3% and 
98.9% diploid coverage of the sAML and normal samples, respectively (Supplementary Table 
1).  We divided the genome into non-overlapping tiers, as previously described4, and validated 
putative mutations using deep sequencing of captured DNA isolated from the sAML, normal, 
and MDS samples.   We validated 507 somatic single nucleotide variants (SNVs) in the sAML 
sample, including 30 SNVs in protein coding regions (tier 1 mutations).  505/507 SNVs 
preexisted in the MDS sample, including 30 tier 1 mutations (Supplementary Fig. 2, 
Supplementary Tables 2, 3).  The same codon in U2AF1 (U2AF35) was mutated in 2 additional 
MDS-derived sAML cases analyzed by whole genome sequencing (data not shown).  This was 
the sole recurrent mutation in these cases.  To determine the frequency of this mutation in MDS, 
we sequenced the entire coding region of U2AF1, including 9 exons, in diagnostic bone marrow 
and paired normal (skin) samples from 150 consecutively accrued de novo MDS patients 
(including the index case) and identified 13 patients (8.7%) with missense mutations affecting 
the highly conserved serine at amino acid position 34 (S34) in U2AF1 (Fig. 1a).  The same 
nucleotide was mutated in all samples, resulting in either a S34F (n=11) or S34Y (n=2) 
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substitution (Supplementary Table 4).  One patient with an S34F mutation (UPN 947519) also 
had a U2AF1 Q157R mutation located in the second zinc finger (Fig. 1a).  No other somatic 
SNVs affecting U2AF1 were detected in these samples.  Subsequent analysis focused on the 
highly recurrent S34 mutations. 
U2AF1 is the small (35 kDa) subunit of U2 snRNP auxiliary factor (U2AF) that is 
involved in pre-mRNA processing (splicing), and it forms a heterodimer with the larger subunit 
U2AF2 (U2AF65)2.  U2AF1 binds the 3’ AG splice acceptor dinucleotide of the pre-mRNA 
target intron2 and U2AF2 binds the adjacent polypyrimidine tract.  PCR amplicons spanning the 
S34 codon were generated from genomic DNA and cDNA templates made from nucleic acids 
harvested from unpurified MDS bone marrow cells, and subjected to deep sequencing to obtain 
mutant allele frequencies.  Importantly, there was no deletion or uniparental isodisomy (UPD) 
that spanned the U2AF1 locus (chromosome 21q22.3) based on SNP arrays and whole genome 
sequencing data for the index case.  Read counts from 11 of the 13 genomic DNA samples 
(including the sAML sample from the index case and serial MDS samples from two other 
patients) showed that the S34 mutant allele frequencies were ~40-50%, indicating that the 
majority of cells in the samples contained a heterozygous mutation, even though the myeloblast 
counts ranged from 0-21% in the MDS samples (Fig. 1b).  Similar results were obtained from 
cDNA deep sequencing (~30-50% mutant allele frequency), indicating that both the S34 mutant 
and wild-type alleles were expressed in all samples, regardless of the myeloblast count (Fig. 1c).  
In addition, there was no difference in the total levels of U2AF1 mRNA or the dominant U2AF1 
isoform that was expressed in unfractionated MDS bone marrow samples from patients with and 
without U2AF1 mutations (Supplementary Fig. 4a).  Collectively, these results suggest that 
U2AF1 mutations are an early, initiating genetic event in MDS pathogenesis.   
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 Although eight of the mutant samples had myeloblast counts > 5%, patients with U2AF1 
mutations were not restricted to a particular International Prognostic Scoring System (IPSS) 
category and had a median IPSS score of 1 (range 0-3) (Supplementary Table 5).  Patients with 
a del(20q) karyotype were more likely to harbor a U2AF1 mutation (P=0.01), although the 
number of patients with mutations and del(20q) is small (n=4) (Table 1).  No difference in 
event-free or overall survival was observed in patients with or without U2AF1 mutations (Fig. 
2a-b).  However, the 2 mutant patients with the longest overall survival had received 
hematopoietic stem cell transplants (Supplementary Fig. 1).  Patients with U2AF1 mutations 
had an increased probability of progression to sAML (P=0.03) (Fig. 2c), an observation that will 
require confirmation in a larger cohort.  This corresponds to a U2AF1 mutation frequency of 
15.2% (7/46 patients) in the subset of MDS patients that progress to sAML vs. 5.8% (6/104 
patients) in the subset that did not.  Since there was no statistical difference in the myeloblast 
count or IPSS distribution of patients with or without U2AF1 mutations (Table 1), the mutant 
genotype does not appear to be a surrogate for these well-established predictors of sAML risk. 
Splicing involves cleavage of intronic sequences from pre-mRNA, followed by ligation 
of the remaining exons together to produce a mature mRNA product8.  Inclusion and exclusion 
of different exons or utilization of alternative 3’ splice sites during pre-mRNA processing 
produces multiple protein isoforms that can have different functions within a cell, and alternative 
splicing can be affected by the levels of U2AF1 in a cell9-12.  It is unknown which domain of 
U2AF1 binds the pre-mRNA.  Interestingly, the S34 and Q157 residues are located within zinc 
finger domains (Fig. 1a) that may be important for RNA binding activity.  Indeed, the U2AF1 
zinc fingers are structurally similar to the murine and human ZFP36 family zinc fingers (both 
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CX8CX5CX3H zinc fingers)13-15 that bind RNA and the noncanonical RNA recognition motif 
(RRM; also known as U2AF homology motif, UHM) in U2AF1 only weakly binds RNA16. 
To examine the effects of the S34F mutation on U2AF1 splicing activity, we utilized 
previously described and validated in vitro double-reporter splicing and minigene reporter 
assays9,17.  The double-reporter plasmid constitutively expresses β-galactosidase, while luciferase 
is expressed only if appropriate splicing removes an upstream intron that contains translational 
stop codons.  Transient co-expression of the double-reporter plasmid pTN24 and the S34F 
mutant U2AF1 cDNA in 293T cells resulted in a significant increase in splicing (as detected by 
an increase in the luciferase/β-galactosidase ratio), compared to co-expression of wild-type 
U2AF1, despite similar total U2AF1 protein levels in all samples (Fig. 3a, P<0.001).  The level 
of splicing was similar in cells depleted of endogenous U2AF1 compared to control cells (Fig. 
3b, left column), and the increase in splicing observed with the S34F mutant U2AF1 is 
independent of endogenous U2AF1 levels (Fig. 3b, right column, P<0.001 when compared to 
vector alone).  This suggests that splicing activity in this assay is insensitive to U2AF1 levels, 
and increased splicing mediated by the mutant protein is attributable to a novel gain-of-function 
activity.   
Next, we examined exon skipping using a minigene reporter plasmid (a human gene 
fragment containing an upstream and downstream exon surrounding an intron-flanked exon).  
Appropriate splicing produces an mRNA with all 3 exons, while exon skipping fuses the 
upstream and downstream exons only.  We measured the levels of exon skipping using a GH1 
minigene reporter plasmid in cells transiently co-transfected with either wild-type or S34F 
mutant U2AF1 cDNA.  The proportion of transcripts with a skipped exon (lower PCR band) 
relative to the appropriately spliced GH1 minigene (upper PCR band) is increased in cells 
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expressing the S34F U2AF1 mutant compared to control or wild-type U2AF1 expression (Fig. 
3c, P=0.01).  This increase in exon skipping mediated by mutant U2AF1 remained significant 
after depletion of endogenous U2AF1 in 293T cells (Fig. 3c, P<0.02).  We also observed an 
increased utilization of alternative 3’ cryptic splice sites in the FMR1 gene in clinical MDS 
samples with U2AF1 mutations compared to MDS samples without U2AF1 mutations 
(Supplementary Fig. 3a).  The alternative splicing of FMR1 was confirmed to be mutant 
U2AF1-dependent using a FMR1 minigene splicing reporter assay in vitro (Supplementary Fig. 
3b). 
Collectively, these results suggest that U2AF1 S34 mutations may result in subtle 
increases in splicing efficiency (Fig. 3a) -- or possibly altered isoform expression (Fig. 3c) -- 
which could induce gene expression changes.  To test whether U2AF1 mutations alter global 
gene expression levels, we analyzed mRNA microarray data (Affymetrix U133plus2) obtained 
from bone marrow CD34+ cells purified from 6 MDS patients with a U2AF1 mutation, 9 MDS 
patients without a mutation, and 4 normal donors18.  The U2AF1 mutant samples did not 
segregate together using an unsupervised hierarchical clustering algorithm with all 19 samples, 
however, the 6 U2AF1 mutant samples did segregate together when compared to the normal 
control samples (Supplementary Fig. 4b).  Next, we identified the genes that were significantly 
different between control and mutant patients using Significance Analysis of Microarrays 
(SAM)19.  SAM identified 401 dysregulated probesets (51 up-regulated and 351 down-regulated) 
in U2AF1 mutant versus control samples (FDR<0.005) (Supplementary Fig. 4b, 
Supplementary Table 6).  Three of the most enriched functional annotation categories for genes 
that are down-regulated in U2AF1 mutant samples are splicing and RNA recognition motif 
(RRM) genes (enrichment scores 2.5-4.3) (Supplementary Fig. 4c, Supplementary Table 6).  
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These results suggest that a compensatory down-regulation of splicing genes may exist in 
U2AF1 mutant samples.  These gene categories were not down-regulated in U2AF1 wild-type 
MDS patients compared to controls (data not shown), suggesting that down-regulation of 
splicing and RRM genes is not common to all MDS samples, but instead is associated with 
U2AF1 mutations. 
Mutations in U2AF1 represent a novel mechanism that could alter gene expression in 
MDS and expand the list of commonly mutated genes in MDS that may affect transcription or 
translation, including RPS14, TET2, EZH2, ASXL1, and DNMT3A20-26.  Only two patients in our 
cohort of 150 de novo MDS samples had both a DNMT3A and U2AF1 mutation 
(Supplementary Table 7).  Both of these mutations appear to be early genetic events in MDS, 
given their high mutant allele burdens in patients with early stage disease26.   
U2AF1 is highly conserved (Fig. 1a)1, and homozygous loss is lethal in many 
organisms27-29.  We did not observe any nonsense, frameshift or missense mutations affecting the 
coordinating CCCH residues in the zinc fingers, again suggesting the S34 mutations are not loss-
of-function mutations.  The corresponding amino acid in the human ZFP36L2 (a ZFP36 family 
member) protein interacts with RNA through a hydrogen bond, further suggesting that the S34 
position may be important for RNA binding13.  Additionally, interactions between conserved 
aromatic amino acids in ZFP36 family members and RNA bases stabilize the protein RNA 
complexes formed13.  The two amino acid substitutions we identified at S34 add a bulky 
aromatic ring (phenylalanine or tyrosine) to the zinc finger, which may alter, or even enhance, 
binding of the zinc finger to RNA.  We suggest that the S34F/Y mutations in U2AF1 alter the 
specificity of U2AF1-dependent splicing.  Pre-mRNAs with strong polypyrimidine tracts can 
splice independently of U2AF1 in vitro, whereas weak polypyrimidine tracts are more dependent 
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on U2AF1 for appropriate splicing2,11.  Therefore, the pattern of U2AF specificity (determined 
by both U2AF1 and U2AF2) may be influenced by the nucleotide sequence in pre-mRNAs and 
may be an important factor in determining which genes are altered in cells expressing mutant 
U2AF1.   
Alternative splicing has been described for a wide range of cancers30,31, although the 
underlying mechanisms that influence cancer pathogenesis remain largely unknown.  Alterations 
in the transcriptome mediated by alternative splicing may contribute directly to cancer, or 
indirectly by engaging some other pathway.  The identification of somatic mutations in 
spliceosome genes in MDS by our group and others32-34, raises the possibility that mutations in 
splicing factors, including U2AF1, may be responsible for the observed alterations of splicing in 
cancer.  Ultimately, cancer cells may generate genetic diversity in a large number of genes by 
selecting cells with mutations in U2AF1 or other spliceosome proteins.  Identification of key 
target genes affected by U2AF1 mutations will be critical for our understanding of how these 
mutations contribute to MDS pathogenesis.  
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FIGURE LEGENDS 
 
Figure 1.  U2AF1 mutations found in patients with myelodysplastic syndromes (MDS).  (a) 
Missense mutations were detected in codons 34 and 157 of U2AF1.  The ZnF1 (zinc finger 1), 
UHM (U2AF homology motif), ZnF2 (zinc finger 2), and RS (arginine-serine rich) domains are 
shown.  The amino acid sequence of the ZnF1 domain is highly conserved (shaded).  The zinc 
coordinating and mutated residue are shown in blue (asterisks) and red (arrow), respectively.  (b)  
Deep sequencing of U2AF1 using DNA collected from paired normal, MDS, or secondary AML 
(sAML) samples.  Mutant allele frequencies represent the proportion of sequencing reads 
supporting the mutant allele reads/total reads.  Total read counts are shown below (mean 5,651 
reads/sample).  The mutation is present in the majority of cells (mutant allele frequency 31.4-
48.2%) in all cases.  (c)  Deep sequencing of cDNA from MDS or sAML samples.  The mutant 
allele is expressed in all cases. UPN, unique patient number. 
 
Figure 2.  Impact of U2AF1 mutations on clinical outcome.  (a) Overall and (b) Event-free 
survival are not impacted by U2AF1 genotype.  (c) The probability of secondary AML (sAML) 
progression is increased in patients with U2AF1 mutations (P=0.03). 
 
Figure 3.  U2AF1 S34F mutation induces splicing alterations.  (a) Transient coexpression of 
the pTN24 double-reporter splicing construct with or without a splicing enhancer (Tra2α), 
splicing inhibitor (hnRNPG), wild-type U2AF1, or mutant (S34F) U2AF1 cDNA in 293T cells.  
The double-reporter construct constitutively expresses β-galactosidase, while luciferase is 
expressed only if an upstream intron which contains multiple stop codons is spliced out.  In the 
absence of the Tra2α splicing enhancer or hnRNPG splicing inhibitor, expression of the mutant 
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U2AF1 increases splicing of the pTN24 construct resulting in an increase in the luciferase/β-
galactosidase expression compared to expression of wild-type U2AF1 (P<0.001).  Tra2α 
(positive control) and hnRNPG (negative control) cause increased or decreased splice efficiency, 
respectively.  A representative Western blot of U2AF1 levels in the same cells used for luciferase 
assays is shown below each combination of plasmids. (b)  Transient coexpression of the pTN24 
double-reporter splicing construct with a control plasmid (vector) or mutant (S34F) U2AF1 
cDNA in the presence of a control siRNA or siRNA targeting the endogenous U2AF1 in 293T 
cells.  Expression of the S34F mutant U2AF1 results in an increase in splicing of the pTN24 
construct with an increase in the luciferase/β-galactosidase expression compared to a control 
plasmid (P<0.001).  The result is independent of endogenous U2AF1 expression levels.  A 
representative Western blot of U2AF1 is shown below each condition. (c)  The GH1 minigene 
was transiently transfected into 293T cells with a control plasmid (pcDNA3.1-YFP), wild-type 
U2AF1 cDNA, or mutant (S34F) U2AF1 cDNA in the presence of a control siRNA or siRNA 
targeting the endogenous U2AF1.  RNA was harvested 48 hours later and a reverse transcriptase 
(RT) reaction was performed to create cDNA.  PCR using the indicated primers resulted in a 
fully spliced 505 base pair amplicon or a 386 base pair amplicon that skips the middle exon 
shaded in black (exon skipping).  A representative PCR gel image is shown and the ratio of the 
lower band (exon skipping = amplicon b) relative to the fully spliced upper band (amplicon a) is 
shown above each condition.  Expression of the S34F mutant U2AF1 results in an increase in 
exon skipping compared to control or wild-type U2AF1 (P<0.02).  bp, base pair; WT, wildtype; 
Mut, mutant; T7, T7 primer.  Error bars, s.d. 
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Table 1.  Patient Characteristics 
 U2AF1 wild-type U2AF1 S34F/Y mutant p-valuea 
    
n  (%) 137 (91.3) 13 (8.7)  
Age at diagnosis  – yr ±SD 61 ±14 59 ±10 0.37b 
range (median) 20-87 (62) 42-79 (59)  
Median survival 975 days 729 days 0.81c 
Gender    
Male  – no.(%) 82 (59.9) 10 (76.9) 0.37 
Blood counts    
WBC (K/mcL) 6 ±11 6 ±11 0.22b 
ANC (K/mcL) 3 ±7 3 ±6 0.43b 
Hb (g/dL) 10 ±2 10 ±2 0.94b 
PLT (K/mcL) 91 ±88 78±66 0.94b 
Bone marrow blasts (%) 6 ±6 8 ±7 0.41 b 
FAB subtype – no.(%)   0.44 
RA 63 (46.0) 4 (30.8)  
RARS 5 (3.7) 0 (0)  
RAEB 64 (46.7) 8 (61.5)  
RAEB-T 5 (3.7) 1 (7.7)  
Cytogenetics – no.(%)    
normal 66 (48.2) 3 (23.1) 0.14 
-Y only 2 (1.5) 0 (0) 1.00 
-5, del(5q) 29 (21.2) 1 (7.7) 0.47 
-7, del(7q) 16 (11.7) 1 (7.7) 1.00 
-17, del(17q) 5 (3.7) 0 (0) 1.00 
del(20q) 8 (5.8) 4 (30.8) 0.01 
+8 16 (11.7) 2 (15.4) 0.66 
complex (≥ 3) 35 (25.6) 1 (7.7) 0.19 
other 15 (11.0) 3 (23.1) 0.19 
not available 4 (2.9) 0 (0) 1.00 
IPSS – no.(%)   0.50 
low 22 (16.1) 1 (7.7)  
INT-1 54 (39.4) 6 (45.2)  
INT-2 37 (27.0) 2 (15.4)  
high 19 (13.9) 4 (30.8)  
not available 5 (3.7) 0 (0)  
WBC, white cell blood count; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelet count; FAB, 
French American British; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, 
refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts, in transformation; IPSS, 
International Prognostic Scoring System. 
a Fisher’s exact, except where indicated;  b Wilcoxon test;  c Log-rank  
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ONLINE METHODS  
Flow sorting of bone marrow samples.  Bone marrow cells from the secondary AML (sAML) 
sample, cryopreserved in 10% DMSO, were rapidly thawed at 37°C, washed, and stained with 
PE-Cy7 conjugated hCD45, clone J.33 (Beckman Coulter), and FITC conjugated anti-hCD34, 
clone 581 (Beckman Coulter).  The blast population (low SSC/CD45 dim) was sorted using a 
Reflection high speed cell sorter (Sony iCyt) directly into lysis buffer and genomic DNA was 
prepared by column purification (Qiagen DNeasy). 
Whole genome sequence production.  Four DNA libraries were generated for paired-end 
sequencing: two from the tumor sample (flow-sorted sAML myeloblasts), and two from the 
normal sample (punch biopsy of unaffected skin).  Sequence data was generated using both 
Illumina GAIIx and Illumina Hiseq platforms in 2 x 100 paired-end reads.  Reads were aligned 
individually to NCBI Build 36 of the human reference sequence using BWA 0.5.5 and SAMtools 
r544.  Alignments were merged into a single BAM file and marked for duplicates using Picard 
1.17 (http://picard.sourceforge.net).  Only non-duplicate reads were used for all downstream 
analyses. 
Somatic mutation detection.  Candidate point mutations were predicted using SomaticSniper (D. 
Larson et al, in press), previously referred to as glfSomatic4,35.  Putative single nucleotide 
variants (SNVs) with somatic score of 40 and average mapping quality of 40 were considered 
high-confidence (HC); all others were deemed low-confidence (LC).  Small (<100 bp) 
insertion/deletion events (indels) were called using a combination of GATK36, IndelGenotyper, 
Pindel37, and a modified version of SAMtools38.  Both SNVs and indels were annotated using 
gene structure and conservation information, and classified by tier as previously described4.  
Briefly, tier 1 contains all changes in the amino acid coding regions of annotated exons, 
consensus splice-site regions, and RNA genes (including microRNA genes).  Tier 2 contains 
changes in highly conserved regions of the genome or regions that have regulatory potential.  
Tier 3 contains mutations in the nonrepetitive part of the genome that do not meet tier 2 criteria, 
and tier 4 contains mutations in the remainder of the genome.  High confidence tier 2 and tier 3 
mutations, and all tier 1 mutations (regardless of confidence) were selected for validation (see 
below).   
 To identify somatic DNA copy number changes from whole genome sequencing (WGS) 
data, reads aligned by BWA39 were binned into contiguous, non-overlapping 1 kb windows.  
Copy number for each bin was normalized to the median copy number for each chromosome in 
tumor and normal separately.  A Hidden Markov Model algorithm40 was used to generate a list 
of segments with copy number expressed as log2 (tumor/normal).  Copy number changes were 
also supported by demonstrating loss of heterozygosity (LOH) in the affected regions.  In brief, 
heterozygous SNPs were identified in WGS data from the normal sample (>10 reads of >q10 
quality with non-reference allele frequencies of 0.4-0.6).  The variant allele frequencies at these 
positions were then averaged in bins of 20 consecutive SNPs and visualized for the normal and 
tumor samples separately.  Deletions, amplifications, inter-, and intrachromsomal 
rearrangements were also predicted using the BreakDancer algorithm41. 
Mutation validation.  To comprehensively evaluate tier 1-3 predictions, we utilized a custom 
solid-phase capture platform.  We selected all tier 1 SNV predictions (HC and LC) and all HC 
tier 2-3 SNVs.  Tier 1-3 indel predictions were also included.  In addition, we used this approach 
to validate SV predictions (deletions and rearrangements).   We identified 8-16 SNPs that were 
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heterozygous in the normal DNA sample (determined using the WGS and SNPa data) that were 
located within the affected segments and 8 SNPs from flanking normal regions.  The genomic 
positions of SNVs and indels (with a 200 bp margin) and SVs (with a 400 bp margin) were 
submitted for probe design.  Probes were synthesized on custom HD2.1 long oligonucleotide 
arrays (Roche NimbleGen).  Whole genome amplified DNA (REPLI-g, Qiagen) from the normal 
(skin), unfractionated MDS, and unfractionated sAML samples was used as bait for capture on 
the arrays and the recovered DNA (enriched for target sequences) was resequenced on the 
Illumina GAIIx platform.   
 At least 10x coverage was obtained for ~87.16% of the target sequence for all samples 
(Supplementary Table 1).  Reads were mapped using BWA39, deduplicated, and merged into 
BAM files.  The reference or somatic status at the nucleotide of interest was then determined for 
each sample using VarScan242 with the following parameters: min-coverage=10, min-var-
freq=0.05, somatic-p-value<0.01, validation=1. To validate low-frequency (2-5%) SNVs, we re-
ran VarScan with adjusted parameters: min-coverage=100, min-var-freq=0.02, somatic-p-
value<0.01, validation=1.  In validation mode, VarScan reads data from tumor and normal 
samples simultaneously, performing pair-wise comparisons at every position covered in both 
samples.  Each position is classified as Reference (wild-type), Germline, LOH, or Somatic, based 
upon a comparison of the consensus genotypes and supporting read counts (Fisher’s Exact test).  
Positions called Somatic are further subjected to our internally-developed false-positive filter 
which removes sequencing- and alignment-related artifacts using several criteria (read count, 
mapping quality, average read position, strand representation, homopolymer-like sequence 
context, mismatch quality sum difference, trimmed read length, Q2 distance) and were manually 
reviewed.  Chromosome X and Y somatic positions are determined using the false-positive filter 
and manual review.  SIFT and PolyPhen2 computational algorithms were used to predict whether 
U2AF1 mutations were damaging, as previously described43,44. 
Sanger sequencing.  To screen for recurrence of U2AF1 mutations, we performed Sanger 
sequencing using whole genome amplified DNA extracted from unfractionated bone marrow 
aspirates and paired normal tissue (skin) from 150 individual patients with de novo MDS.  PCR 
amplicons covering all 9 exons and splice sites in U2AF1 were sequenced using BigDye 
chemistry and analyzed on an ABI 3730 sequencer (primer sequences in Supplementary Table 
8).  Sequence variants were called by The Genome Institute’s mutational profiling pipeline and 
manually reviewed.  Potential somatic mutations (present in the bone marrow sample and not 
detectable in skin) were confirmed by independent PCR and sequencing. 
Deep sequencing of U2AF1 mutations in DNA and cDNA.  Unfractionated bone marrow 
samples from 11 patients with validated U2AF1 mutations were selected for deep sequencing to 
estimate clone size.  Whole genome amplified DNA from normal (skin), MDS, and sAML 
samples were amplified by PCR individually using barcoded primers (Supplementary Table 8).  
The products were then pooled and sequenced on the Roche/454 platform.  In parallel, RNA was 
extracted from MDS and sAML samples (Trizol, Invitrogen), converted to cDNA using the 
Ovation RNA-seq Kit (NuGEN), and amplified with barcoded primers spanning intron/exon 
boundaries (Supplementary Table 8).  Reads were aligned to Hs36 using BWA-SW39.  
Following alignment, BAM and pileup files were generated using SAMtools and analyzed by 
Picard to remove duplicates.  Only uniquely mapped bases with >q20 scores were retained.  
Reads supporting the reference or variant allele were identified by VarScan2. 
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SNP array analysis.  Genomic DNA samples (not subjected to whole genome amplification) 
from the normal, MDS, and sAML specimens (not flow-sorted) were hybridized to Affymetrix 
6.0 SNP arrays (Affymetrix, Inc.).  Analysis of copy number alterations and copy neutral loss of 
heterozygosity was performed using the Partek Genomics Suite (Partek, Inc). 
mRNA expression profiling.  Total RNA was harvested from unfractionated bone marrow cells 
(69% myeloblast) from the secondary AML sample from UPN 266395 and hybridized to the 
Affymetrix Exon 1.0 ST array.  Raw data was extracted using the Affymetrix Expression 
Console (Affymetrix, Inc.) and analyzed in Prism 5.04 (GraphPad Software, Inc.).   
Total RNA was harvested from CD34+ purified MDS bone marrow samples (n=15) and control 
bone marrow (n=4) and hybridized to the Affymetrix U133plus2 array, as previously reported18.  
Supervised hierarchical clustering was performed using Ward’s clustering algorithm with a 
Euclidean distance similarity measure in Spotfire (TIBCO Software Inc).  Significance Analysis 
of Microarrays (SAM), Gene Set Enrichment Analysis (GSEA), and Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 were performed as previously 
described19,45,46. 
Reverse transcriptase PCR.  cDNA was made from RNA using Moloney Murine Leukemia 
Virus (M-MLV) reverse transcriptase or Superscript III kit (Invitrogen).  Quantitative real-time 
RT-PCR was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) 
(primer and probe sequences for GAPDH are provided in47).  The U2AF1 primer and probe set 
spans exons 2-3 (Hs00739599_m1, Applied Biosystems).  All samples were run in duplicate on a 
7300 Real-Time PCR system (Applied Biosystems) and analyzed using the relative standard 
curve method.  Non-quantitative RT-PCR for U2AF1 mRNA isoform expression was performed 
and loaded on a 10% polyacrylamide gel (Forward: 5’-GCCTCCATCTTCGGCACCGA-3’, 
Reverse: 5’-GGCATGGCTCAGAATCGCCC-3’).   
Generation of U2AF1 expression plasmids.  RNA from a patient bone marrow biopsy (UPN 
571656) was used to generate both U2AF1 (wildtype) and U2AF1 (S34F mutant) expression 
vectors.  cDNA was generated from patient bone marrow RNA using Superscript III kit 
(Invitrogen).  Both wild type and mutant U2AF1 cDNAs were obtained via PCR amplification, 
cloned with the Topo Cloning kit (Invitrogen), and sequenced for verification.  The U2AF1 
cDNAs were then shuttled into the EcoRI site of the pcDNA3.1+ vector (Invitrogen) for transient 
transfection experiments.   
Luciferase-β-galactosidase double-reporter assay.  293T cells were seeded in a 6-well plate (1 x 
106 per well) and cultured in DMEM (Gibco/Invitrogen) supplemented with 10% FBS and L-
glutamine.  Following overnight culture, cells were co-transfected with the expression vectors 
(U2AF1 wildtype or S34F mutant, or empty vector) and the pTN24 splicing reporter plasmid 
(containing a constitutively expressed β-galactosidase reporter for transfection normalization and 
a luciferase reporter that is conditional on removal of a translational stop codon by splicing) with 
or without splicing modulators hnRNPG and Tra2α17.  In some experiments, cells were also co-
transfected with 30nM U2AF1-specific siRNA (5’-CGUAGAAAGUGUUGUAGUUGAUUGA-
3’; IDT, Inc.) or 30nM siRNA scramble control (Dharmacon).  Cells were harvested 48 hours 
following transfection, and reporter expression was detected, as previously described17 using the 
Dual Light Reporter System (Applied Biosystems) and analyzed by calculating the ratio of 
luciferase to β-galactosidase signal.  Changes in U2AF1 levels were confirmed by Western blot 
using antibodies specific for U2AF1 (SAS1300700, Sigma-Aldrich) or β-actin (A5441, Sigma-
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Aldrich) as a loading control.  Three independent experiments were performed and the data was 
analyzed using a Student’s t-test. 
Minigene constructs and transfection.  293T cells were cultured and transfected with U2AF1 
expression vectors, as above.  Cells were also co-transfected with a GH1 minigene splicing 
reporter construct9.  In other experiments, cells were co-transfected with a FMR1 minigene 
splicing reporter construct containing partial sequence from exons 14 and 15 and the complete 
intronic sequence.  Amplification of the FMR1 DNA fragment (including the intron) was 
achieved using the FMR1-201 E15 set of primer sequences previously published10.  The 
amplified fragment was cloned into the TopoTA vector (Invitrogen), purified following BamH1 
and XhoI digestion, and subsequently cloned into pcDNA3.1 (Invitrogen).  Co-transfection of 
U2AF1 or control siRNAs was also performed, as above.  Cells were harvested 48 hours 
following transfection, and RNA was extracted using the RNeasy reagent (Qiagen) following the 
manufacturer’s instructions.  The RNA was used as a template for cDNA synthesis via RT-PCR 
with random hexamers and oligo(dT) primers.  Changes in minigene splicing were then 
measured by PCR of the cDNA using a T7 forward primer and gene-specific reverse primers as 
previously described9,10 and quantified by densitometry.  U2AF1 knockdown by siRNA and 
U2AF1 reconstitution were confirmed by Western blot analysis, as above.  Three to four 
independent experiments were performed and the data was analyzed using a Student’s t-test. 
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